GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40938)

  • GC81496 structure
    GC81496TAVO101
    Purity: >96.50%

    TAVO101 is a humanized anti- TSLP antibody with an EC 50 of 0.19 nM against hTSLP.

  • GC81497 structure
    GC81497Vadalentamig
    CAS: 3030203-93-8
    Purity: >95.00%

    Vadalentamig is a human-derived bispecific antibody targeting NKG2D/CD314 & ERBB1/EGFR/HER1 [1] .

  • GC81500 structure
    GC81500Ac-rG Phosporamidite- 15 N
    CAS: 1799973-39-9
    Purity: >98.00%

    Ac-rG Phosporamidite - 15 N (5'-DMT-2'-TBDMS-rG(N-Ac) Phosphoramidite- 15 N) is the 15 N-labeled Ac-rG Phosporamidite.

  • GC81501 structure
    GC81501Ac-rG Phosporamidite- 13 C
    Purity: >98.00%

    Ac-rG Phosporamidite - 13 C (5'-DMT-2'-TBDMS-rG(N-Ac) Phosphoramidite- 13 C) is the 13 C-labeled Ac-rG Phosporamidite.

  • GC81502 structure
    GC81502Ac-rG Phosporamidite- 13 C 10
    Purity: >98.00%

    Ac-rG Phosporamidite - 13 C 10 (5'-DMT-2'-TBDMS-rG(N-Ac) Phosphoramidite- 13 C 10 ) is the 13 C-labeled Ac-rG Phosporamidite.

  • GC81503 structure
    GC815035'(E)-VP-2'-OMe-U phosphoramidite
    CAS: 2172373-55-4
    Purity: >98.00%

    5'(E)-VP-2'-OMe-U Phosphoramidite is a phosphoramidite nucleotide precursor compound, mainly used to synthesize stable and functionalized modified oligonucleotides for the research and synthesis of nucleic acid drugs.

  • GC81504 structure
    GC815045'-Amino-modifier spacer 9 Phosphoramidite
    CAS: 3048248-99-0
    Purity: >98.00%

    5'-Amino-modifier spacer 9 Phosphoramidite is a modified phosphoramidite monomer that can be used for the synthesis of oligonucleotides.

  • GC81505 structure
    GC81505Spacer phosphoramidite 9
    CAS: 146668-73-7
    Purity: >98.00%

    Spacer phosphoramidite 9 (Spacer-9 CEP) is a Phosphoramidite.

  • GC81506 structure
    GC81506Reverse abasic phosphoramidite
    CAS: 401813-16-9
    Purity: >98.00%

    Reverse abasic phosphoramidite is a reverse abasic phosphoramidite modifier for oligonucleotide synthesis and can be used to introduce reverse abasic modifications into oligonucleotides.

  • GC81507 structure
    GC81507S-cEt-U phosphoramidite
    CAS: 945628-51-3
    Purity: >98.00%

    S-cEt-U phosphoramidite is a modified phosphoramidite monomer that can be used for the oligonucleotide synthesis [1] .

  • GC81508 structure
    GC81508Unylinker-OH Resin (Substitution:300±25 µmol/g)
    Purity: >98.00%

    Unylinker-OH Resin (Substitution:300±25 µmol/g) is a macroporous polystyrene resin functionalized with Unylinker active groups with uniform particle size and uniform active groups.

  • GC81509 structure
    GC81509DMTr-2'-O-C22-rU-3'-CE-phosphoramidite
    CAS: 2923115-86-8
    Purity: >98.00%

    DMTr-2'-O-C22-rU-3'-CE-phosphoramidite is an RNA phosphoramidite monomer.

  • GC81510 structure
    GC81510Denatonium benzoate-d 5
    Purity: >99.50%

    Denatonium benzoate -d 5 (THS-839-d 5 ) is the deuterium labeled Denatonium benzoate.

  • GC81511 structure
    GC81511BCN-CE-phosphoramidite
    CAS: 1393524-83-8
    Purity: >96.00%

    BCN-CE-phosphoramidite is an oligonucleotide modifier containing a BCN strained cyclooctyne structure.

  • GC81512 structure
    GC81512dCDK9-202
    Purity: >98.50%

    dCDK9-202 is a CDK9 PROTAC degrader with a DC 50 of 3.5 nM.

  • GC81513 structure
    GC81513SMARCA2/4-ligand-8
    CAS: 2380272-41-1
    Purity: >99.50%

    SMARCA2/4-ligand-8 is a SMARCA2/4 ligand, which can be used for the synthesis of PROTACs, such as PROTAC SMARCA2/4-degrader-26 [1] .

  • GC81514 structure
    GC81514PROTAC SMARCA2 degrader-35
    CAS: 3032998-97-0
    Purity: >98.00%

    PROTAC SMARCA2 degrader-35 (Compound 43) is a selective SMARCA2 PROTAC degrader with a DC 50 < 0.1 μM for SMARCA2.

  • GC81515 structure
    GC81515BMS-986482
    CAS: 3062993-48-7
    Purity: >98.00%

    BMS-986482 is a CRBN -mediated IKZF1-4 ( Ikaros family zinc finger 1-4 ) molecular glue degrader.

  • GC81516 structure
    GC81516BMS-986482 acetate
    Purity: >98.00%

    BMS-986482 acetate is a CRBN -mediated IKZF1-4 ( Ikaros family zinc finger 1-4 ) molecular glue degrader.

  • GC81517 structure
    GC81517(Rac)-BMS-986449
    Purity: >99.00%

    (R)-BMS-986449 is the racemic mixture of BMS-986449.

  • GC81519 structure
    GC81519SHP1-IN-2
    Purity: >97.00%

    SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor.

  • GC81520 structure
    GC81520Cinflumide
    CAS: 64379-93-7
    Purity: >99.50%

    Cinflumide is an orally active muscle relaxant.

  • GC81521 structure
    GC815212',3'-ddA(N-Bz) Phosphoramidite
    Purity: >98.00%

    2',3'-ddA(N-Bz) Phosphoramidite is a modified phosphoramidite monomer that can be used for the synthesis of oligonucleotides.

  • GC81522 structure
    GC81522WWZ-11-098
    Purity: >98.00%

    WWZ-11-098 is a selective CDK6 PROTAC degrader with DC 50 of 2.6 nM.